Combating Antibacterial Resistance: The Integrative Role of Artificial Intelligence in Bio-Based Product Development

Area of Science:

• Microbiology
• Drug Discovery
• Bioinformatics

Background:

• Antimicrobial resistance (AMR) causes nearly 5 million deaths annually, with economic losses projected to reach $300 billion by 2030.
• Traditional antibiotic discovery pipelines face significant bottlenecks, including the unculturability of 99.9% of environmental microbes and low annotation rates for biosynthetic gene clusters.
• Existing antibiotics are becoming obsolete due to sophisticated bacterial resistance mechanisms like extended-spectrum β-lactamases and multidrug efflux pumps.

Purpose of the Study:

• To review how artificial intelligence (AI) is transforming bio-based antibacterial discovery.
• To analyze AI-driven tools for identifying novel antimicrobial compounds from natural sources.
• To demonstrate AI's impact on overcoming traditional limitations in antibiotic research.

Main Methods:

• AI-driven genome mining to identify biosynthetic gene clusters.
• Deep learning models for predicting compound bioactivity.
• Generative models for designing novel antibacterial agents.
• Analysis of AI applications from in silico prediction to in vivo efficacy.

Main Results:

• AI tools have identified over 170,000 biosynthetic gene clusters.
• Deep learning achieved 88.5% bioactivity prediction accuracy.
• Generative models yielded experimental hit rates exceeding 50%, a 50- to 90-fold improvement over traditional screening.
• Validated case studies demonstrate AI's effectiveness in accelerating discovery and accessing novel chemical diversity.

Conclusions:

• AI integration is fundamentally transforming antibacterial discovery by accessing previously inaccessible natural chemical diversity.
• AI significantly accelerates the identification and development of novel bio-based antibiotics.
• AI offers a powerful solution to the urgent global threat of antimicrobial resistance.